2023 annual results and publication postponement for Aton

During its meeting on April 26, 2024, Aton (Hybrigenics SA - Euronext Growth Paris - FR0004153930 - ALHYG), active in the medical sciences sector, presented its 2023 annual results but postponed the publication of its annual report. This, initially scheduled for April 30, 2024, was delayed following the impossibility for the auditor to certify the accounts due to uncertainties over the continuity of operations.

Aton's turnover for 2023 stands at 0.4 million euros, mainly thanks to the centralized management of services at its subsidiaries. The group recorded an operating result of -0.8 million euros and a very affected financial result, at -12.8 million, mainly due to the depreciation of the shares of its subsidiaries Inoviem Scientific and Stemcis. The net result for the year is -18.8 million euros. On the balance sheet, shareholders' equity shows -4.7 million euros as of December 31, 2023.